Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1α

Journal of Immunotherapy

Volumn 22, Issue 3, 1999, Pages 251-259

  Woodlock, Timothy J ^a,b   Sahasrabudhe, Deepak M ^a   Marquis, Diana M ^a   Greene, Dori ^a   Pandya, Kishan J ^a,b   McCune, Craig S ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Saint Marys Hospital   (United States)

^c Missoula Medical Oncology   (United States)

Author keywords

Active specific immunotherapy; Cancer vaccine; Colorectal carcinoma; Interleukin 1

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1ALPHA; PHOSPHORYL LIPID A;

ACTIVE IMMUNIZATION; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DRUG EFFECT; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPOTENSION; MALE; METASTASIS; PRIORITY JOURNAL; PRURITUS; RIGOR;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CANCER VACCINES; COLONIC NEOPLASMS; FEMALE; HEPATITIS B ANTIBODIES; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-1; LIPID A; MALE; MIDDLE AGED; MYCOBACTERIUM; NEOPLASM METASTASIS; RECTAL NEOPLASMS; SKIN TESTS; TREATMENT OUTCOME;

EID: 0032915621     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199905000-00008     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J Clim 1997;47:8.
2. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: DeVita VT Jr, Heilman S, Rosenberg SA. Cancer: principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott, 1993:962.
3. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-62.
4. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor associated glycoprotein (tag-72) using monoclonal antibody B72.3. Cancer Res 1986;46:850-7.
5. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994;343:1177-83.
6. Blumberg N, Heal JM. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Am J Med 1996;101:299-308.
7. Rosenberg SA. Adoptive cellular therapy: clinical applications. In: DeVita VT Jr, Heilman S, Rosenberg SA. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:217-9.
8. Hoover HC Jr, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
9. McCune CS, Schapira DV, Henshaw ED. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 1981;47:1984-7.
10. Gery I, Gershon RK, Waksman BH. Potentiation of the T-Lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972;136:128-38.
11. Feldman M. Cell cooperation and the antibody response. In: Roitt I, Brostoff J, Male D. Immunology, 4th ed. London: Mosby, 1996:8.1-.9.
12. McCune C. Interleukin-1 as an adjuvant for tumor vaccines increases survival in mice. Biotherapy 1989;1:355-9.
13. McCune C, Marquis D. Interleukin-1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 1990;50:1212-5.
14. McCune CS, O’Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990;32:62-6.
15. Szmuness V, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-41.
16. Berd D, Maguire HC Jr., McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
17. Unanue ER. Macrophages, antigen-presenting cells, and the phenomena of antigen handling and presentation. In: Paul WE. Fundamental immunology, 3rd ed. New York: Raven Press, 1993:119-21.
18. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
19. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biological and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996;88:2819-25.
20. Smith JW II, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992;10:1141-52.
21. Weisdorf D, Katsanis E, Verfaillie C, et al. Interleukin-1 administered after autologous transplantation: a phase I/II clinical trial. Blood 1994;84:2044-9.
22. Olsson L, Ebbesen P. Natural polyclonality of spontaneous AKR leukemia and its consequences for so-called specific immunotherapy. J Natl Cancer Inst 1979;62:623-6.
23. Sugarbaker EV, Cohen AM. Altered antigenicity in spontaneous pulmonary metastases from an antigenic murine sarcoma. Surgery 1972;72:155-61.
24. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-93.